Pre-made Cibisatamab benchmark antibody (Bispecific mAb with Domain Crossover, anti-CEACAM5/CD66e;CD3E therapeutic antibody, Anti-CEA;T3E/TCRE/IMD18 Antibody) for drug discovery and mechanism of action (MOA) research

Cat No.: GMP-Bios-ab-104

Anti-CEACAM5/CD66e;CD3E therapeutic antibody (Pre-made Cibisatamab biosimilar,Bispecific mAb with Domain Crossover, Anti-CEA;T3E/TCRE/IMD18 Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Cibisatamab, an investigational drug, is a bispecific antibody, which means it binds to two different proteins: one called CEACAM5 on the surface of some colorectal cancer cells and another on T cells called CD3.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-104-1mg 1mg Inquiry
GMP-Bios-ab-104-10mg 10mg Inquiry
GMP-Bios-ab-104-100mg 100mg Inquiry
GMP-Bios-ab-104-xmg ≥100mg Inquiry
Shipping Cost: 760.00


Products Name (INN Index) Pre-Made Cibisatamab biosimilar, Bispecific mAb with Domain Crossover: Anti-CEACAM5;CD3E therapeutic antibody
INN Name Cibisatamab
FormatBispecific mAb with Domain Crossover
DerivationBispecific antibody
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa;Lambda
Highest_Clin_Trial (Jan '20)Phase-I/II
Est. StatusActive
100% SI StructureNone;None
99% SI StructureNone;None
95-98% SI StructureNone;None
Year Proposed2017
Year Recommended2018
Conditions Approvedna
Conditions ActiveNon-small cell lung cancer;Colorectal cancer
Conditions DiscontinuedSolid tumours
Development Techna